Novartis

Visiongain Launches Report Examining the Potential in the $23bn Wearable Medical Devices Market | PR Newswire | 11/11/2019

… Samueli School of Engineering and Applied Science Hexoskin Hocoma iHealth Integrity Applications InteraXon Jawbone KLAS Loon Lab, Inc. Massive Health Mayo Clinic Medtronic Monica Healthcare MTN Nemaura Medical Neofect NeuroMetrix, Inc. NightBalance Nike Nokia Novartis Nuvo Omron Pebble Polar Electro Practice GreenHealth Preventice Prima-Temp ProNav Proteus Digital Health ReSound ReWalk Royal Philips N.V . Samsung SGS United Kingdom Limited Siemens Healthcare Sleep Image SoftTech VC Sotera Wireless, Inc, Starkey Hearing …

Roche’s challenger for SMA market hits goal in phase 3 | FierceBiotech | 11/11/2019

… trial of Roche’s risdiplam in patients with type 2 or 3 spinal muscular atrophy (SMA) has met its primary endpoint. The results tee Roche up to file for approval to compete with Biogen and Novartis in the increasingly crowded SMA market. Roche’s phase 3 clinical trial enrolled patients with less severe forms of the muscle wasting disease. While people with type 1 SMA typically die by the age of two …

Follow Novartis:    

Novartis’ Sandoz, still working on U.S. slim-down, bets on Japan with Aspen deal | FiercePharma | 11/11/2019

by Angus Liu Nov 11, 2019 10:52am Novartis is beefing up its hospital portfolio in Japan through a deal to buy Aspen Pharmacare’s local operations for up to €400 million. (Getty Images) Novartis’ Sandoz has yet to nail down its generics selloff to Aurobindo Pharma, but that hasn’t stopped it from pursuing deals outside the troublesome U.S. market. The Novartis generics unit has penned a deal to buy Aspen Pharmacare …

Lupin sells off Japanese operation to tidy up its balance sheet | FiercePharma | 11/11/2019

… buying the Japanese operations of South Africa’s Aspen Pharmacare for up to €400 million. In that case, Aspen will continue to manufacture drugs for Sandoz for up to seven years. That deal comes as Novartis has yet to complete a $1 billion sale of some plants and a portfolio of 300 drugs to India’s Aurobindo as it tries to remake its exposure in the difficult U.S. generics market. Read more …

The Week Ahead In Biotech: Adcom Test For Amarin’s Fish Oil Pill, Agile Awaits FDA Verdict | Yahoo News | 11/11/2019

After the previous week’s strong gains, biotech stocks experienced a slight loss of momentum this week. The week saw a few clinical trial readouts and a slew of earnings reports from small- to mid-sized biotechs. The FDA approved Sanofi SA’s (NASDAQ: SNY ) Fluzone for older adults and Novartis AG’s (NYSE: NVS ) Sandoz unit’s Neulasta biosimilar. REDHILL BIOPHAR/S ADR (NASDAQ: RDHL )’s H. Pylori treatment was also OK’ed by …

Cryoport: Cold Chain Is A Hot Business Model - Cryoport, Inc. (NASDAQ:CYRX) | Seeking Alpha | 11/11/2019

… and supply chain logistics, it is critical to ensure reliable “vein to vein” delivery. In this regard, it is worth noting that Cryoport is currently the sole source logistics supplier to Gilead ( GILD ) and Novartis ( NVS ) for Yescarta and Kymriah, respectively, and it will be involved with the 2020 introduction of bluebird bio’s ( BLUE ) Zynteglo. Additionally, and in my opinion underappreciated, Cryoport announced earlier this week an agreement with Lonza …

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/11/2019

… and I’ll squeeze one more in. Do you guys have any updates on the Kymriah BLA submission in China? Tony Liu We on that one, again, thanks for the question. We continue work with Novartis on that. We’re making progress as planned. So far, it’s on track. So it is both sides, both Novartis and CBMG, we’re pleased with the progress and we continue to move forward with that. And …

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations | Zacks | 11/11/2019

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Novartis AG ’s ( NVS - Free Report ) generic unit Sandoz announced that it has entered an agreement to acquire the Japanese business of Aspen Global Incorporated (AGI), a wholly-owned subsidiary of Aspen Pharmacare …

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J | 11/11/2019

… Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk ( NVO - Free Report ) , Allergan ( AGN - Free Report ) , Sanofi ( SNY - Free Report ) , Novartis ( NVS - Free Report ) and J&J ( JNJ - Free Report ) . Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: AGN, NVO, SNY and More It was a relatively quieter week for the pharma sector, barring …

Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day | 11/11/2019

… of the Day, C.H. Robinson Worldwide, Inc. ( CHRW - Free Report ) asthe Bear of the Day. In addition, Zacks Equity Research provides analysis on Tilray ( TLRY - Free Report ) , Anheuser-Busch InBev ( BUD - Free Report ) and Novartis ( NVS - Free Report ) . Here is a synopsis of all five stocks: Bull of the Day : Shares of Chegg have surged over 15% since the company posted stronger-than-projected third-quarter financial results on November …

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market | Globe Newswire | 11/11/2019

November 11, 2019 01:00 ET Source: Novartis International AG Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Planned acquisition reinforces Sandoz strategic focus on Japan Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital …

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Swiss Stock Exchange:NOVN | Globe Newswire | 11/11/2019

… political, economic and industry conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update …

ImmunoGen: Profiting And Turning Around - ImmunoGen, Inc. (NASDAQ:IMGN) | Seeking Alpha | 11/11/2019

… wings of its validated ADC technology. Most notable is the giant Swiss Pharma, Roche ( ROG ) that employs ImmunoGen’s ADC for its flagship drug (Kadcyla). Other firms using ImmunoGen’s validated technology include Eli Lilly ( LLY ), Novartis ( NVS ), Sanofi ( SNY ), and Takeda. Despite the ambiguous Mirve data, the fact that many reputable companies are using ImmunoGen’s technology is solid proof in the pudding of its leadership in ADC. Figure 2: Therapeutic pipeline …

Narcolepsy Market 2019 Analysis Along with Major Vendors as Bioprojet,Teva Pharmaceutical Industries Ltd.,Jazz Pharmaceuticals, Inc.,Graymark Healthcare, Inc., etc | 11/11/2019

… the market are studied specifically to give profound knowledge for supplementary market investments. Request a Sample of Narcolepsy Market Research Report and Analysis of Top Key Players at https://www.theinsightpartners.com/sample/TIPRE00003326/ Companies Mentioned :- Novartis AG, Mylan N.V. Shionogi Inc. Detailed segmentation of the market, on the basis of Type, Distribution Channel, product, Geography and a descriptive structure of trends of the segments and sub-segments are elaborated in the …

Anti-Asthmatics and COPD Drugs Market Emerging Trend, Technological Growth, Business Growth Statistics and High Demand – Novartis , Merck & Co , GlaxoSmithKline , Boehringer Ingelheim | 11/11/2019

… a CAGR of 5.9% through 2022. North America was the largest region in the anti-asthmatics and COPD drugs market in 2017. Major Key Players of the Anti-Asthmatics and COPD Drugs Market are: Novartis , Merck & Co , GlaxoSmithKline , Boehringer Ingelheim Gmbh , AstraZeneca , Roche , Teva Pharmaceutical , Vectura , Pfizer , Abbott , Mylan , Allergan , Cipla , Akorn Get sample copy of “Anti-Asthmatics and COPD Drugs Market” at: https://www.reportsweb.com/inquiry&RW00012923088/sample Modifiable risk …

NKMax America Announces Executive Advisory Board | PR Newswire | 11/11/2019

SANTA ANA, Calif. NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that it has brought together an unparalleled group of thought leaders to provide expertise to the NKMax senior leadership team. The Executive Advisory Board will cover key areas of strategic corporate development with a particular focus on industry partnerships and clinical advisement in …

Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global Medicines Company Novartis | 11/11/2019

Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global Medicines Company Novartis Submitted by: Novartis Posted: Nov 11, 2019 – 01:00 AM EST • Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme • Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two …

Psoriasis Drugs Market 2019 by Emerging Trend, High Demand, Supply Scenarios and Business Development – AbbVie , Pfizer , Novartis , Eli Lilly and Company , Celgene | 11/11/2019

… the largest during the next five years. The psoriasis drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023. Major Key Players of the Psoriasis Drugs Market are: AbbVie , Pfizer , Novartis , Eli Lilly and Company , Celgene , Johnson & Johnson , Amgen , Boehringer Ingelheim , Merck & Co , Janssen Biotech , Takeda Pharmaceutical Company Limited , Stiefel Laboratories , AstraZeneca , UCB , Sun Pharmaceutical Industries Ltd , Forward Pharma , Almirall , Valeant Pharmaceuticals , Biogen Idec , Biocon , Celltrion …

UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target | 11/11/2019

UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target 24 min ago Reuters Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. [ Read More ] 48 48 48 50 …

Roche sets sights on Novartis, Biogen as SMA trial hits target | News | WIN 98.5 | 11/11/2019

ZURICH (Reuters) - Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to …

Clinical Data

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/11/2019

… our approach has been to prioritize and institutionalize distinguishable manufacturing process that is repeatable and can help us ensure quality clinical data. Having seen our early clinical feedback, I remain cautiously optimistic that we can … one, again, thanks for the question. We continue work with Novartis on that. We’re making progress as planned. So far, it’s on track. So it is both sides, both Novartis and CBMG, we’re pleased with …

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market | Globe Newswire | 11/11/2019

November 11, 2019 01:00 ET Source: Novartis International AG Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Planned acquisition reinforces Sandoz strategic focus on … development, including clinical trial results and additional analysis of existing clinical data; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency …

Big Pharma

Roche’s challenger for SMA market hits goal in phase 3 | FierceBiotech | 11/11/2019

… SMA) has met its primary endpoint. The results tee Roche up to file for approval to compete with Biogen and Novartis in the increasingly crowded SMA market. Roche’s phase 3 clinical trial enrolled patients with … phase 2/3 trial at an upcoming medical congress. The Swiss Big Pharma is also working to generate data from another study that enrolled patients with type 1 SMA. If the data support a 2020 approval …

Reverse Brain Drain, Commercial-Espionage And Patent Infringements: The Good, Bad And Ugly Of Biopharma - AstraZeneca PLC (NYSE:AZN) | Seeking Alpha | 11/11/2019

… world’s second largest healthcare market. Comprehensive trials, speedier approvals and faster-to-market drug approvals are the norms. No wonder big pharma is looking eastward! It’s advantage China all the way. AstraZeneca plc ( AZN ) is … BMY ), Eli Lilly ( LLY ), GlaxoSmithKline (NYSE: GSK ), Merck ( MRK ), and Novartis ( NVS ). The financial and technological investments in China by the multinationals are quite apart from the medical technology and scientific expertise developed by the …

Biosimilars

Novartis’ Sandoz, still working on U.S. slim-down, bets on Japan with Aspen deal | FiercePharma | 11/11/2019

by Angus Liu Nov 11, 2019 10:52am Novartis is beefing up its hospital portfolio in Japan through a deal to buy Aspen Pharmacare’s local operations for up to €400 million. (Getty Images) Novartis’ Sandoz has … an intensified focus on hard-to-copy generics, injectables and biosimilars. As part of that pivot, Novartis has agreed to sell some under-pressure U.S. generic oral solids and dermatology meds to India’s Aurobindo for …

Roche’s New Oncology Drugs To Add $5 Billion In Sales By 2021? | Forbes | 11/11/2019

… Myers Squibb’s Opdivo In Lung Cancer Drugs Market. Perjeta And Kadcyla Are Used For The Treatment of HER2 Positive Breast Cancer. Another Key Drug In This Market Is Roche’s Herceptin. Smaller Drugs Include Novartis’ Tykerb And Puma Biotechnology’s Nerlynx. Alecensa Is Used For The Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. It Competes With Pfizer’s Xalkori. Other Smaller Drugs Include Takeda’s Alunbrig And Novartis’ Zykadia. Related …

Digital Health

Visiongain Launches Report Examining the Potential in the $23bn Wearable Medical Devices Market | PR Newswire | 11/11/2019

Novartis Nuvo Omron Pebble Polar Electro Practice GreenHealth Preventice Prima-Temp ProNav Proteus Digital Health ReSound ReWalk Royal Philips N.V . Samsung SGS United Kingdom Limited Siemens Healthcare Sleep Image SoftTech VC Sotera Wireless, Inc, Starkey Hearing Technologies Step of Mind True ventures Unilife Corporation Ventech Viatom Viatom Technology Visere Vital Connect VivoSensMedical Volcano Corporation WalkJoy, Inc. Wearable Robotics Withings Zephyr Technology List of Other Organizations Mentioned in the Report AAMI …

Interview with OnDigital Health Consulting released for Disruptive Technologies in Pharma 2020 | 11/9/2019

… regarding his views and expectations on the conference and on the current developments within the industry. Karl Hess is a digital health and population health management platform ecosystem builder, leader, investor and evangelist, as well … Joseph Dalton, Global Lead Digital Health Solutions and Medical Outcomes, Novartis • Umair Aslam, e-Health Lead, MSD • Dr Andrew Bate, Senior Director, Analytics Team Lead, Pfizer • Bhushan Bonde, Head of IT - Early …

Precision Medicine

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer | 11/11/2019

… implications. Conflicts of Interest E.B. received honoraria or speakers’ fee from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; E.B. also received research grants from I.A.S.L.C. (International Association for the Study … metabolite regulation of host defenses at mucosal surfaces: implication in precision medicine,” Precision Clinical Medicine , vol. 2, no. 2, pp. 110–119, 2019. View at Publisher · View at Google Scholar M. Sun, W. Wu, L …

ImmunoGen: Profiting And Turning Around - ImmunoGen, Inc. (NASDAQ:IMGN) | Seeking Alpha | 11/11/2019

… ROG ) that employs ImmunoGen’s ADC for its flagship drug (Kadcyla). Other firms using ImmunoGen’s validated technology include Eli Lilly ( LLY ), Novartis ( NVS ), Sanofi ( SNY ), and Takeda. Despite the ambiguous Mirve data, the fact that many … Mirve will bank huge profits due to the power of precision medicine. In other words, FORWARD 1 let ImmunoGen know that high FRA patients will respond positively. By focusing on the high FRA-expressed group …

Regenerative Medicine

The Week Ahead In Biotech: Adcom Test For Amarin’s Fish Oil Pill, Agile Awaits FDA Verdict | Yahoo News | 11/11/2019

… earnings reports from small- to mid-sized biotechs. The FDA approved Sanofi SA’s (NASDAQ: SNY ) Fluzone for older adults and Novartis AG’s (NYSE: NVS ) Sandoz unit’s Neulasta biosimilar. REDHILL BIOPHAR/S ADR (NASDAQ: RDHL )’s … 8-13 in Atlanta, Georgia 12th International Conference on Tissue Engineering & Regenerative Medicine: Nov. 11-12 in Madrid, Spain 28th Annual Credit Suisse Healthcare Conference: Nov. 11-13 in Scottsdale, Arizona 13th International Congress on Autoimmunity: Nov. 12-13 …

Cryoport: Cold Chain Is A Hot Business Model - Cryoport, Inc. (NASDAQ:CYRX) | Seeking Alpha | 11/11/2019

… main growth driver over the past four years has been related to biopharmaceuticals, which is experiencing tremendous growth in the regenerative medicine segment. This area includes cell therapy, gene therapy and gene-based therapy. According … currently the sole source logistics supplier to Gilead ( GILD ) and Novartis ( NVS ) for Yescarta and Kymriah, respectively, and it will be involved with the 2020 introduction of bluebird bio’s ( BLUE ) Zynteglo. Additionally, and in my …

Clinical Research

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer | 11/11/2019

… diet and eating habits. These variables are closely related to geographical location, suggesting therefore the need of more in-depth clinical research studies, looking at ethnic diversity as well as eating habits and environment-related … from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; E.B. also received research grants from I.A.S.L.C. (International Association for the Study of Lung Cancer), L.I.L.T. (Lega Italiana per la Lotta contro …

Selonsertib misses endpoint, provides future trial design insight | 11/11/2019

… to see what we can glean from a study of this magnitude,” Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, said during his presentation. “Data from these trials provide important … HighTide, HistoIndex, Innovate, Intercept, IQVIA, Lipocine, Madrigal, Medpace, Metacrine, NGM, Novartis, Novo Nordisk, Perspectum, Pfizer, Poxel, PPD, Prometheus, Prometic and Terns; is on the speakers bureau with Alexion; and has received research support from Allergan …

National Institutes of Health

Reverse Brain Drain, Commercial-Espionage And Patent Infringements: The Good, Bad And Ugly Of Biopharma - AstraZeneca PLC (NYSE:AZN) | Seeking Alpha | 11/11/2019

… in a trade war with China. Now it has opened another can of worms targeting researchers of Chinese descent. The National Institutes of Health (NIH) and the Federal Bureau of Investigation (FBI) have started a … BMY ), Eli Lilly ( LLY ), GlaxoSmithKline (NYSE: GSK ), Merck ( MRK ), and Novartis ( NVS ). The financial and technological investments in China by the multinationals are quite apart from the medical technology and scientific expertise developed by the …

NKMax America Announces Executive Advisory Board | PR Newswire | 11/11/2019

… Boston -based Venture Capital Firm investing over $750 M for the biotech and healthcare technology space. Mr. de Groot spent the early part of his career in regulatory and commercial executive positions at Novartis, GSK and Millennium Pharmaceuticals/Takeda and holds an MBA from The University of Chicago Booth School of Business. Mr. de Groot has guest lectured on the subject of venture investing and entrepreneurship at the University of …

Pain Management

Visiongain Launches Report Examining the Potential in the $23bn Wearable Medical Devices Market | PR Newswire | 11/11/2019

… Monitoring & Obstetric Devices • Glucose Monitoring Devices • Sleep Monitoring Devices • Others • Global Therapeutic Wearable Medical Devices Market revenues forecast from 2019-2029 • Pain Management Devices • Diabetes Management Wearable Devices • Rehabilitation Devices • Respiratory Therapy Wearable Devices • Others • Global … Healthcare MTN Nemaura Medical Neofect NeuroMetrix, Inc. NightBalance Nike Nokia Novartis Nuvo Omron Pebble Polar Electro Practice GreenHealth Preventice Prima-Temp ProNav Proteus Digital Health ReSound ReWalk Royal Philips N.V . Samsung SGS United Kingdom Limited …

Expansion of Human Pluripotent Stem Cell-derived Early Cardiovascular Progenitor Cells by a Cocktail of Signaling Factors | Nature | 11/5/2019

… Care and Use of Laboratory Animals. Immunosuppression was performed by subcutaneous (SC) administration of 15 mg/kg/day cyclosporine A (Novartis Pharma AG) two days before surgery to seven days post-MI. During the remainder … Iran) for three days to prevent infection and to perform pain management, respectively. At the end of the study, rats were euthanized using CO 2 inhalation. Echocardiographic assessment Cardiac function was evaluated in rats by …

Pain Management

Visiongain Launches Report Examining the Potential in the $23bn Wearable Medical Devices Market | PR Newswire | 11/11/2019

… Monitoring & Obstetric Devices • Glucose Monitoring Devices • Sleep Monitoring Devices • Others • Global Therapeutic Wearable Medical Devices Market revenues forecast from 2019-2029 • Pain Management Devices • Diabetes Management Wearable Devices • Rehabilitation Devices • Respiratory Therapy Wearable Devices • Others • Global … Healthcare MTN Nemaura Medical Neofect NeuroMetrix, Inc. NightBalance Nike Nokia Novartis Nuvo Omron Pebble Polar Electro Practice GreenHealth Preventice Prima-Temp ProNav Proteus Digital Health ReSound ReWalk Royal Philips N.V . Samsung SGS United Kingdom Limited …

Expansion of Human Pluripotent Stem Cell-derived Early Cardiovascular Progenitor Cells by a Cocktail of Signaling Factors | Nature | 11/5/2019

… Care and Use of Laboratory Animals. Immunosuppression was performed by subcutaneous (SC) administration of 15 mg/kg/day cyclosporine A (Novartis Pharma AG) two days before surgery to seven days post-MI. During the remainder … Iran) for three days to prevent infection and to perform pain management, respectively. At the end of the study, rats were euthanized using CO 2 inhalation. Echocardiographic assessment Cardiac function was evaluated in rats by …

Pfizer

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer | 11/11/2019

… Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; E.B. also received research grants from I.A.S.L.C. (International Association for the Study of Lung Cancer), L.I.L.T. (Lega Italiana per la Lotta contro i Tumori), Fondazione Cariverona, Astra-Zeneca, Roche, and Open Innovation, not related to the submitted work. S.P. reports personal fees from Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, Roche, MSD, and Istituto Gentili, outside the submitted work. G.T. reports grants …

Selonsertib misses endpoint, provides future trial design insight | 11/11/2019

… Novartis, Novo Nordisk, Perspectum, Pfizer, Poxel, PPD, Prometheus, Prometic and Terns; is on the speakers bureau with Alexion; and has received research support from Allergan, Axcella, Cirius, Conatus, CymaBay, Galectin, Galmed, Genfit, Gilead, HighTide, Immuron, Intercept, Madrigal, NGM, Novartis, Novo Nordisk, Pfizer, Second Genome and Tobira. This study was funded by Gilead. Stephen A. Harrison BOSTON — While selonsertib did not demonstrate efficacy as a monotherapy in patients with nonalcoholic steatohepatitis …

Merck

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer | 11/11/2019

… implications. Conflicts of Interest E.B. received honoraria or speakers’ fee from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; E.B. also received research grants from I.A.S.L.C. (International Association for the Study … reports grants and others from Celgene, Novartis, Roche, Incyte, and Merck Serono and grants from Fondazione Cariverona, outside the submitted work. The remaining authors have nothing to disclose. Authors’ Contributions Giampaolo Tortora and Emilio Bria …

Biotechnology Market Size Worth $741.7 Billion by 2026 | CAGR 7.7% | 11/11/2019

… Merck, PerkinElmer, Qiagen, Thermo Fisher Scientific, Gilead, Celgene, Novo Nordisk A/S, Novartis AG, Sanofi Aventis, and Lonza. ABOUT US -Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology …

GlaxoSmithKline

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations | Zacks | 11/11/2019

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … biotech sector are Bristol-Myers Squibb Company ( BMY - Free Report ) , GlaxoSmithKline plc. ( GSK - Free Report ) and Merck & Co. Inc. ( MRK - Free Report ) , all sporting a Zacks Rank 2 (Buy). You can see the complete list …

Reverse Brain Drain, Commercial-Espionage And Patent Infringements: The Good, Bad And Ugly Of Biopharma - AstraZeneca PLC (NYSE:AZN) | Seeking Alpha | 11/11/2019

GlaxoSmithKline (NYSE: GSK ), Merck ( MRK ), and Novartis ( NVS ). The financial and technological investments in China by the multinationals are quite apart from the medical technology and scientific expertise developed by the NIH with taxpayers’ money that the U.S. federal officials say the Chinese startups are founded on. Like I said, while there may be some truth in those claims, the US government and the American public should not lose focus …

Bristol-Myers Squibb

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations | Zacks | 11/11/2019

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … A few better-ranked stocks in the biotech sector are Bristol-Myers Squibb Company ( BMY - Free Report ) , GlaxoSmithKline plc. ( GSK - Free Report ) and Merck & Co. Inc. ( MRK - Free Report ) , all sporting a Zacks Rank 2 …

Selonsertib misses endpoint, provides future trial design insight | 11/11/2019

… Bristol-Myers Squibb, Cirius, Civi, CLDF, ConSynance, ContraVir, Corcept, CymaBay, Echosens, Galectin, Galmed, Gilead, HighTide, HistoIndex, Innovate, Intercept, IQVIA, Lipocine, Madrigal, Medpace, Metacrine, NGM, Novartis, Novo Nordisk, Perspectum, Pfizer, Poxel, PPD, Prometheus, Prometic and Terns; is on the speakers bureau with Alexion; and has received research support from Allergan, Axcella, Cirius, Conatus, CymaBay, Galectin, Galmed, Genfit, Gilead, HighTide, Immuron, Intercept, Madrigal, NGM, Novartis, Novo Nordisk, Pfizer, Second Genome and Tobira …

AbbVie

Drug Makers Agreed to Settle Illinois Claims They Inflated Rates | 11/11/2019

… GlaxoSmithKline LLC, Johnson & Johnson, Inc., Janssen Pharmaceutical Products, LP, McNeil-PPC, Inc., Ortho Biotech Products, LP, Ortho-McNeil Pharmaceutical, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacia Corporation, and TAP Pharmaceutical Products, Inc. Since 2004, Miner … 1.4 million to $18.96 million, including those for Abbott Laboratories, Abbvie, Aventis, Pharmacia Corporation, Forest Laboratories, B. Braun Medical and TAP Pharmaceuticals. In addition to representing the state of Illinois, Miner, Barnhill & Galland has represented …

Psoriasis Drugs Market 2019 by Emerging Trend, High Demand, Supply Scenarios and Business Development – AbbVie , Pfizer , Novartis , Eli Lilly and Company , Celgene | 11/11/2019

AbbVie , Pfizer , Novartis , Eli Lilly and Company , Celgene , Johnson & Johnson , Amgen , Boehringer Ingelheim , Merck & Co , Janssen Biotech , Takeda Pharmaceutical Company Limited , Stiefel Laboratories , AstraZeneca , UCB , Sun Pharmaceutical Industries Ltd , Forward Pharma , Almirall , Valeant Pharmaceuticals , Biogen Idec , Biocon , Celltrion Inc. , Dr.Reddy’s Laboratories Get sample copy of “Psoriasis Drugs Market” at: https://www.reportsweb.com/inquiry&RW00012923085/sample The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused …

GSK

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations | Zacks | 11/11/2019

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … are Bristol-Myers Squibb Company ( BMY - Free Report ) , GlaxoSmithKline plc. ( GSK - Free Report ) and Merck & Co. Inc. ( MRK - Free Report ) , all sporting a Zacks Rank 2 (Buy). You can see the complete list of today’s …

Reverse Brain Drain, Commercial-Espionage And Patent Infringements: The Good, Bad And Ugly Of Biopharma - AstraZeneca PLC (NYSE:AZN) | Seeking Alpha | 11/11/2019

GSK ), Merck ( MRK ), and Novartis ( NVS ). The financial and technological investments in China by the multinationals are quite apart from the medical technology and scientific expertise developed by the NIH with taxpayers’ money that the U.S. federal officials say the Chinese startups are founded on. Like I said, while there may be some truth in those claims, the US government and the American public should not lose focus of the …

Bristol-Myers

Roche’s New Oncology Drugs To Add $5 Billion In Sales By 2021? | Forbes | 11/11/2019

Bristol-Myers Squibb’s Opdivo In Lung Cancer Drugs Market. Perjeta And Kadcyla Are Used For The Treatment of HER2 Positive Breast Cancer. Another Key Drug In This Market Is Roche’s Herceptin. Smaller Drugs Include Novartis’ Tykerb And Puma Biotechnology’s Nerlynx. Alecensa Is Used For The Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. It Competes With Pfizer’s Xalkori. Other Smaller Drugs Include Takeda’s Alunbrig And Novartis’ Zykadia …

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations | Zacks | 11/11/2019

Novartis’ Generics Unit to Buy Aspen’s Japanese Operations Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide … A few better-ranked stocks in the biotech sector are Bristol-Myers Squibb Company ( BMY - Free Report ) , GlaxoSmithKline plc. ( GSK - Free Report ) and Merck & Co. Inc. ( MRK - Free Report ) , all sporting a Zacks Rank 2 …

Biogen

Roche’s challenger for SMA market hits goal in phase 3 | FierceBiotech | 11/11/2019

Nov 11, 2019 8:00am Roche will share full data from the phase 2/3 trial at an upcoming medical congress. (Roche) A phase 3 trial of Roche’s risdiplam in patients with type 2 or 3 spinal muscular atrophy (SMA) has met its primary endpoint. The results tee Roche up to file for approval to compete with Biogen and Novartis in the increasingly crowded SMA market. Roche’s phase 3 clinical trial enrolled …

Psoriasis Drugs Market 2019 by Emerging Trend, High Demand, Supply Scenarios and Business Development – AbbVie , Pfizer , Novartis , Eli Lilly and Company , Celgene | 11/11/2019

Novartis , Eli Lilly and Company , Celgene , Johnson & Johnson , Amgen , Boehringer Ingelheim , Merck & Co , Janssen Biotech , Takeda Pharmaceutical Company Limited , Stiefel Laboratories , AstraZeneca , UCB , Sun Pharmaceutical Industries Ltd , Forward Pharma , Almirall , Valeant Pharmaceuticals , Biogen Idec , Biocon , Celltrion Inc. , Dr.Reddy’s Laboratories Get sample copy of “Psoriasis Drugs Market” at: https://www.reportsweb.com/inquiry&RW00012923085/sample The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused due to …

Allergan

The Week Ahead In Biotech: Adcom Test For Amarin’s Fish Oil Pill, Agile Awaits FDA Verdict | Yahoo News | 11/11/2019

… earnings reports from small- to mid-sized biotechs. The FDA approved Sanofi SA’s (NASDAQ: SNY ) Fluzone for older adults and Novartis AG’s (NYSE: NVS ) Sandoz unit’s Neulasta biosimilar. REDHILL BIOPHAR/S ADR (NASDAQ: RDHL )’s … Dates The FDA on Monday is expected to rule on Allergan plc’s (NYSE: AGN ) NDA for Ubrogepant in the treatment of migraines. Agile Therapeutics Inc (NASDAQ: AGRX ) awaits word from the FDA on Saturday on …

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J | 11/11/2019

Read More Hide Full Article For Immediate Release Chicago, IL – November 11, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk ( NVO - Free Report ) , Allergan ( AGN - Free Report ) , Sanofi ( SNY - Free Report ) , Novartis ( NVS - Free Report ) and J&J …

Celgene

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer | 11/11/2019

… Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis, and Roche; E.B. also received research grants from I.A.S.L.C. (International Association for the Study of Lung Cancer), L.I.L.T. (Lega Italiana per la Lotta contro i Tumori), Fondazione Cariverona, Astra-Zeneca, Roche, and Open Innovation, not related to the submitted work. S.P. reports personal fees from Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, Roche, MSD, and Istituto Gentili, outside the submitted work. G.T. reports …

Biotechnology Market Size Worth $741.7 Billion by 2026 | CAGR 7.7% | 11/11/2019

… Celgene, Novo Nordisk A/S, Novartis AG, Sanofi Aventis, and Lonza. ABOUT US -Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductor Contact us …

Jefferies Financial Group

Novartis (NYSE:NVS) Lifted to “Hold” at ValuEngine | 11/11/2019

Novartis (NYSE:NVS) Lifted to “Hold” at ValuEngine Posted by Amber Abramson on Nov 10th, 2019 Tweet ValuEngine upgraded shares of Novartis (NYSE:NVS) from a sell rating to a hold rating in a research … shares of Novartis in a report on Friday, July 5th. Jefferies Financial Group reaffirmed a buy rating on shares of Novartis in a report on Thursday, August 29th. Finally, Zacks Investment Research cut shares of …

Novartis AG (NYSE:NVS) Stake Lowered by Keybank National Association OH | 11/11/2019

Keybank National Association OH cut its stake in shares of Novartis AG (NYSE:NVS) by 9.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The … 23rd. They noted that the move was a valuation call. Jefferies Financial Group reiterated a “buy” rating on shares of Novartis in a research report on Thursday, August 29th. Cowen reiterated a “buy” rating and …

SVB Leerink

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… microdystrophin program and working with many of the Zolgensma and Spinraza sites treating SMA. Based on the very strong results Novartis demonstrated with their recent launches of Zolgensma and understanding the label and the differences … year. Operator Our next question comes from Joseph Schwartz of SVB Leerink. Your line is open. Unidentified Analyst Hi, good evening. Thanks for taking my questions. This is Dae Gon [ph] dialing in for Joe …

Sarepta Therapeutics (SRPT) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… dystrophin program and working with many of the Zolgensma and Spinraza sites treating SMA. Based on the very strong results Novartis demonstrated with their recent launch of Zolgensma and understanding the label and the differences … year. Operator Our next question comes from Joseph Schwartz of SVB Leerink. Your line is open. Dae Gon – SVB Leerink – Analyst Hi, good evening. Thanks for taking the question. This is Dae Gon dialing in …

Merrill Lynch

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/8/2019

… Whitney Ijem - Guggenheim Christopher Marai - Nomura Brian Abrahams - RBC Capital Markets Debjit Chattopadhyay - H.C. Wainwright Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Salveen Richter - Goldman Sachs Danielle Brill - Piper Jaffray Joel Beatty … Spinraza sites treating SMA. Based on the very strong results Novartis demonstrated with their recent launches of Zolgensma and understanding the label and the differences in patient population sizes between the two disease states, we …

Sarepta Therapeutics (SRPT) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/8/2019

… dystrophin program and working with many of the Zolgensma and Spinraza sites treating SMA. Based on the very strong results Novartis demonstrated with their recent launch of Zolgensma and understanding the label and the differences … America. Your line is open. Tazeen Ahmad – Bank of America Merrill Lynch – Analyst Hi. Good afternoon, guys. Thanks for taking my question. Just wanted to get a sense, Doug, about the timing of the readout …

Morgan Stanley

Ionis Pharmaceuticals, Inc. (IONS) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/7/2019

… revenue increased by more than 65% to $377 million. R&D revenue included $198 million in license fee revenue from Novartis GSK and Alnylam; $100 million from amortization of upfront payment for advancing numerous programs … much. Our next question will come from David Lebowitz with Morgan Stanley. Please go ahead. David Neil Lebowitz – Morgan Stanley – Analyst Would you be able to give us a run-through of the recent HBV …

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… the data at ASH. Operator Our next question comes from Terence – I’m sorry, the question comes from Matthew Harrison from Morgan Stanley. Your line is now open. Matthew Harrison – Morgan Stanley – Analyst Great. Good morning … for some years. But specifically to the most recent launch, Novartis’ launch, when you take all the important competition seriously and certainly have been prepared for new market entrants. But it is really early, so …

Goldman Sachs

🌎 The Weekly Wrap-Up for 11/2/2019 | 11/2/2019

… Talked About Upgrades and Downgrades Airbus ( EPA:AIR ) was given a new €161.00 ($187.21) price target on by analysts at Goldman Sachs Group Inc on Wednesday. They now have a “buy” rating on the stock … of $31.93. This rating was viewed 102 times. Read More . Novartis ( VTX:NOVN ) was given a new CHF 82 price target on by analysts at JPMorgan Chase & Co. on Wednesday. They now have a “sell …

AbbVie Inc (ABBV) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/1/2019

… of Investor Relations Thanks Navin. Operator, next question please. Operator Thank you. Our next question is from Terence Flynn from Goldman Sachs. Terence Flynn – Goldman Sachs Group – Analyst Hi, good morning. Thanks for taking the … economics? The second question is on psoriatic arthritis. So both Novartis and Lilly have failed to show ACR-20 improvements in front-line setting versus HUMIRA. Given you are awaiting data next year for your …

William Blair

🌎 The Weekly Wrap-Up for 11/2/2019 | 11/2/2019

… current price of $5.46. This rating was viewed 117 times. Read More . argenx ( NASDAQ:ARGX ) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating on Thursday. current price … of $31.93. This rating was viewed 102 times. Read More . Novartis ( VTX:NOVN ) was given a new CHF 82 price target on by analysts at JPMorgan Chase & Co. on Wednesday. They now have a “sell …

Neogenomics Inc (NEO) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/29/2019

… well as assays for other new indications. We have talked at length about PIK3CA, which is the companion diagnostic for Novartis Piqray, and have seen uptake that is even better than we expected. We also … Kevin. We’ll take our next question from Brian Weinstein with William Blair. Brian Weinstein – William Blair – Analyst Hey, guys, thanks for taking the questions. First, can you talk about the impact on sustainability of test …

Citigroup

AbbVie Inc (ABBV) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/1/2019

… Steve. Operator, next question please. Operator Thank you. Our next question is from Andrew Baum from Citi. Andrew Simon Baum – Citigroup Inc – Analyst Thank you. Couple of questions please. First on Washington. Obviously it’s very … economics? The second question is on psoriatic arthritis. So both Novartis and Lilly have failed to show ACR-20 improvements in front-line setting versus HUMIRA. Given you are awaiting data next year for your …

IPO Update: Galera Therapeutics Proposes IPO Terms - Galera Therapeutics (Pending:GRTX) | Seeking Alpha | 10/29/2019

… in Galera include HBM Healthcare Investments, New Enterprise Associates, Rock Springs Capital, Adage Capital Management, Tekla Capital Management, Correlation Ventures, Novartis Venture Fund ( NVS ), Novo Ventures, Clarus Ventures, and Sofinnova Investments among others. Source: Crunchbase … available here . Listed underwriters of the IPO are BofA Securities, Citigroup, BTIG, and Credit Suisse. Commentary Galera is seeking public capital to advance its pipeline of treatments for conditions that occur during the treatment of …

Andreessen Horowitz

Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | 11/1/2019

… hormone that helps the body regulate iron absorption. —Tmunity Therapeutics, a University of Pennsylvania developing next-generation T cell cancer therapies in Philadelphia, raised a $75 million Series B financing round led by Andreessen Horowitz. — Wisconsin’s Venture Investors, the oldest venture firm in Wisconsin, has raised a sixth fund totaling $75 million . In a departure from its broader focus with previous funds, the new fund will invest only in early …

Why We’re Investing in Tmunity | 10/31/2019

… and Dr. Bruce Levine . Their pioneering work led to the approval of the world’s first CAR T therapy in 2017, Novartis’ Kymriah , for the treatment of certain leukemias and lymphomas. CAR T is a medical … we might cure cancer. I am thrilled to announce that Andreessen Horowitz is leading the Series B financing for Tmunity, joining investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, Be The Match …

Venture Investors

Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | 11/1/2019

… the body regulate iron absorption. —Tmunity Therapeutics, a University of Pennsylvania developing next-generation T cell cancer therapies in Philadelphia, raised a $75 million Series B financing round led by Andreessen Horowitz. — Wisconsin’s Venture Investors, the oldest venture firm in Wisconsin, has raised a sixth fund totaling $75 million . In a departure from its broader focus with previous funds, the new fund will invest only in early-stage life sciences …

Rani Therapeutics Hires First CFO | PR Newswire | 5/10/2019

… venture investors, and has partnered with Novartis and Shire Pharmaceuticals, among others. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran , a prolific medical inventor, entrepreneur, and investor. Mir has founded more than 20 life sciences companies and holds more than 400 issued and pending patents in the …

Biogen Idec

Visiongain Report Provides Critical Market-led Data on the $8.3bn Pre-Filled Device Manufacturing Market | PR Newswire | 10/31/2019

… Solutions (part of Baxter) Baxter International Bayer BD Medico Becton, Dickinson & Co. (BD) Berlin-Chemie Berry Plastics Group Bespak Biocon Biogen Idec Bionime Blackstone Group Boehringer Ingelheim Boehringer Ingelheim BioXcellence Bristol- Myers Squibb C.R. Bard … of Nipro) Nipro Medical (part of Nipro) Nipro North America Novartis Novo Nordisk Nuova Ompi (Formerly Ompi, Italian part of Stevanato Group) Nycomed Nycomed (part of Takeda) Nypro Occupational Safety and Health Administration ( OSHA) [US …

Global Auto-Injectors Market Analysis 2019-2025 : Antares Pharma, Inc., Biogen Idec, Mylan, Inc., Novartis International AG, Sanofi | 10/31/2019

Global Auto-Injectors Market Analysis 2019-2025 : Antares Pharma, Inc., Biogen Idec, Mylan, Inc., Novartis International AG, Sanofi 1 min ago Ann.Castro The “ Auto-Injectors Market “ report includes an in-depth analysis of the global Auto-Injectors market for the present as well as forecast period. The report encompasses the competition landscape entailing share analysis of the key players in the Auto-Injectors market based on their revenues and other significant …

Mayo Clinic

Visiongain Launches Report Examining the Potential in the $23bn Wearable Medical Devices Market | PR Newswire | 11/11/2019

Mayo Clinic Medtronic Monica Healthcare MTN Nemaura Medical Neofect NeuroMetrix, Inc. NightBalance Nike Nokia Novartis Nuvo Omron Pebble Polar Electro Practice GreenHealth Preventice Prima-Temp ProNav Proteus Digital Health ReSound ReWalk Royal Philips N.V . Samsung SGS United Kingdom Limited Siemens Healthcare Sleep Image SoftTech VC Sotera Wireless, Inc, Starkey Hearing Technologies Step of Mind True ventures Unilife Corporation Ventech Viatom Viatom Technology Visere Vital Connect VivoSensMedical Volcano Corporation WalkJoy, Inc …

The Vaccine Program: Betrayal of Public Trust & Institutional Corruption—Part 4 of 7 | 11/11/2019

… by the Editor-in-Chief, Gregory Poland. [44] Dr. Poland’s direct conflicts of interest [45] include those disclosed on the Mayo Clinic website: “ Dr. Poland is the chairman of a safety evaluation committee for investigational … Racke has received personal compensation for activities with EMD Serone, Novartis, Roche Diagnostics Corporation, Genentech, and Amarantus as a consultant.” [EMD Serono, Inc. is a subsidiary of Merck KGaA, Darmstadt, Germany.] How is it that …

Harvard Medical School

HF pharmacotherapy in midst of paradigm shift | 11/8/2019

… 26% in patients with HFrEF with and without diabetes. In PARAGON-HF, the angiotensin receptor/neprilysin inhibitor sacubitril/valsartan (Entresto, Novartis) narrowly missed its primary endpoint of reduction of CV death and HF hospitalizations in … Edward D. Frohlich Distinguished Chair and professor of medicine at Harvard Medical School, senior physician at Brigham and Women’s Hospital and executive committee co-chair of PARAGON-HF, said during the HFSA Scientific Meeting that …

How A Computer Model Prices the Value Of Good Health and Moderates Drug Costs | 11/7/2019

… using it to shame drug manufacturers to lower their prices. The Institute for Clinical and Economic Review, an outgrowth of Harvard Medical School with no political affiliation or official policy-making role, has latched onto … such as Elizabeth Warren, pharmaceutical companies have started paying attention. Novartis AG set the price of its lifesaving gene therapy Zolgensma at the limit suggested by ICER, as the Boston group is known. Dave Lennon …

Cleveland Clinic

HF pharmacotherapy in midst of paradigm shift | 11/8/2019

… 26% in patients with HFrEF with and without diabetes. In PARAGON-HF, the angiotensin receptor/neprilysin inhibitor sacubitril/valsartan (Entresto, Novartis) narrowly missed its primary endpoint of reduction of CV death and HF hospitalizations in … Starling, MD, MPH, FACC, FESC, FHFSA, professor of medicine at Cleveland Clinic and immediate past president of HFSA, said in an interview. “It also shows there were no safety concerns. It shows us potentially, depending …

Quanterix Corporation Releases Operating Results for Third Quarter 2019 | Business Wire | 11/6/2019

… growing momentum for clinical validity of this marker. Serum-based Nf-L measurements were reported in major trials, such as Novartis’ Phase III ASCLEPIOS trial, Roche’s results for Phase III OPERA I, II and ORATORIO … Forum and the Healthcare CEO Summit in partnership with the Cleveland Clinic. We were also featured on “Nasdaq Spotlight” where we discussed ourbiomarker potential to enable precision health and participated in an interview withthe author …

UPMC

Pharmacy Leaders and Technology Innovators Convene in Miami Beach | Globe Newswire | 11/4/2019

… Novartis, Pfizer, Prime Therapeutics, UPMC Health Plan and WEGO Health. Additional presentations will be delivered by Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Sean Creehan, founder of creehan & company and pharmacy fellow at Inovalon. “Patient outcomes are the measurement of success in healthcare, and that’s especially true in the specialty pharmacy model,” said Matt Brow, president & general manager, pharmacy, life sciences and advisory …

MD Anderson Cancer Center

Immunotherapy Added to CT Might Just Work in Bladder Cancer | 11/3/2019

… the largest trial in advanced bladder cancer so far, involving 1213 patients, noted study leader Enrique Grande, MD, of the MD Anderson Cancer Center Madrid, Spain. Speaking here during a press briefing at the European … Squibb, Ipsen, Roche, Eisai, EUSA Pharma, MSD, Sanofi Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, Celgene, Astellas, Janssen, Bayer, AstraZeneca, and Molecular Templates. Durán reports relationships with Roche-Genentech, BMS, MSD, Janssen, AstraZeneca, Seattle Genetics, Pharmacyclics …

Reuters Health News Summary | Yahoo News | 11/2/2019

… a strain of the bacteria called Salmonella Dublin, according to the Centers for Disease Control and Prevention. (http://bit.ly/2N7RuPu) Novartis says delayed telling FDA of Zolgensma concern due to ‘mistake’ Novartis scientists learnt months … Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said on Friday. If confirmed, Hahn, a radiation oncologist who has …

Providence St. Joseph Health

Tech giants like Google and Amazon are beefing up their healthcare strategies. Here’s how 7 tech titans plan to tackle the $3.5 trillion industry. | Business Insider | 11/3/2019

Novartis , Humana, and West Coast-based health system Providence St. Joseph Health . In addition to providing cloud services, Microsoft also commits to working with its partners on projects. For instance, with Walgreens, it plans to test out health offerings, including 12 pilot “digital health corners” in stores. Those are in the process of being executed, Peter Lee , the corporate vice president of Microsoft Healthcare told Business Insider at the HLTH …

Dispensed: A trip to rural Pennsylvania, the final word on uBiome, and the looming cloud wars in healthcare | Business Insider | 10/4/2019

Novartis . From Walgreens, to West Coast-based health system Providence St. Joseph Health, to now Novartis, it’s been interesting to see where Microsoft is going deep on AI partnerships in addition to selling its cloud services. We’ve seen others take similar approaches, like Minnesota-based Mayo Clinic in September signed Google on as its cloud and AI partner, while the health information technology giant Cerner said it had made Amazon …

St. Joseph Health

Tech giants like Google and Amazon are beefing up their healthcare strategies. Here’s how 7 tech titans plan to tackle the $3.5 trillion industry. | Business Insider | 11/3/2019

Novartis , Humana, and West Coast-based health system Providence St. Joseph Health . In addition to providing cloud services, Microsoft also commits to working with its partners on projects. For instance, with Walgreens, it plans to test out health offerings, including 12 pilot “digital health corners” in stores. Those are in the process of being executed, Peter Lee , the corporate vice president of Microsoft Healthcare told Business Insider at the HLTH …

Dispensed: A trip to rural Pennsylvania, the final word on uBiome, and the looming cloud wars in healthcare | Business Insider | 10/4/2019

Novartis . From Walgreens, to West Coast-based health system Providence St. Joseph Health, to now Novartis, it’s been interesting to see where Microsoft is going deep on AI partnerships in addition to selling its cloud services. We’ve seen others take similar approaches, like Minnesota-based Mayo Clinic in September signed Google on as its cloud and AI partner, while the health information technology giant Cerner said it had made Amazon …

University of Texas MD Anderson Cancer Center

Reuters Health News Summary | Yahoo News | 11/2/2019

… a strain of the bacteria called Salmonella Dublin, according to the Centers for Disease Control and Prevention. (http://bit.ly/2N7RuPu) Novartis says delayed telling FDA of Zolgensma concern due to ‘mistake’ Novartis scientists learnt months … to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said on Friday. If confirmed, Hahn, a radiation …

Massachusetts General Hospital

Study Examines Kidney Injury in Patients Taking Immunotherapy Cancer Medications | 11/1/2019

… the frequency, severity, and predictors of acute kidney injury (AKI) associated with these drugs, Meghan Sise, MD, Harish Seethapathy, MBBS (Massachusetts General Hospital), and their colleagues examined information on all patients who received immune checkpoint … a consultant or on advisory boards of Merck, Amgen, Array, Novartis, Genentech, Replimmune and Compugen. Meghan Sise has received research funding from Gilead and EMD-Serono and has been a scientific advisory board member for …

University of Pittsburgh Medical Center

Second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study | BMJ | 11/1/2019

… MD, PhD (University of Glasgow, Glasgow, UK); P. Wirtz, MD, PhD (HagaZiekenhuis, The Hague, The Netherlands); S.A. Zivkovich, MD, PhD (University of Pittsburgh Medical Center, Pittsburgh, USA). Contributors CV: Study concept and design, patient inclusion … Behring, DP Clinical, Grifols, Hansa Medical, Karos Pharmaceuticals, Neurocrine Biosciences, Novartis, Octapharma, Pharnext, Seattle Genetics, Sun Pharmaceuticals, and Syntimmune. He is on the data and safety monitoring board for Sanofi, Pledpharma, Pfizer, Johnson Roche, Sanofi …

Aetna

Tech giants like Google and Amazon are beefing up their healthcare strategies. Here’s how 7 tech titans plan to tackle the $3.5 trillion industry. | Business Insider | 11/3/2019

… also increasingly using data from the watch and other Apple devices in studies . Apple’s also been working with insurers like Aetna and UnitedHealthcare . In the case of Aetna, the program is wagering that an app … high-profile partnerships with the likes of companies like Walgreens , Novartis , Humana, and West Coast-based health system Providence St. Joseph Health . In addition to providing cloud services, Microsoft also commits to working with its …

Behavioral health providers affiliate to aid in transition to value-based payments | Crain’s New York Business | 10/30/2019

… Novartis, SAP and Urban Outfitters. Henry is in-network for major dental plans such as Aetna, Cigna, Delta Dental and UnitedHealthcare. Its services are billed to those insurers at no extra cost to employers. The company is able to perform preventive and restorative dentistry, such as fillings, and its dentists and hygienists are employees. Clinicians return to offices multiple times a year to establish a relationship with patients. A patient …

Humana

Tech giants like Google and Amazon are beefing up their healthcare strategies. Here’s how 7 tech titans plan to tackle the $3.5 trillion industry. | Business Insider | 11/3/2019

Novartis , Humana, and West Coast-based health system Providence St. Joseph Health . In addition to providing cloud services, Microsoft also commits to working with its partners on projects. For instance, with Walgreens, it plans to test out health offerings, including 12 pilot “digital health corners” in stores. Those are in the process of being executed, Peter Lee , the corporate vice president of Microsoft Healthcare told Business Insider at the HLTH …

Insurance Vs. Generic Pricing: The Good, Bad, And Ugly Of Biopharma | Seeking Alpha | 10/28/2019

Insurance company versus big pharma - whose money is it anyway? Humana Inc. (NYSE: HUM ), a $39 billion health insurance company, accuses Teva Pharmaceutical Industries (NYSE: TEVA ), an $8 billion company, and a few other generic … Actavis (merged into Allergan (NYSE: AGN ) now), Mylan (NASDAQ: MYL ), Novartis (NYSE: NVS ), and Teva among nearly 30 other drug makers related to 16 generic drugs. Humana threw its hat in the ring of ongoing …

UnitedHealthcare

Tech giants like Google and Amazon are beefing up their healthcare strategies. Here’s how 7 tech titans plan to tackle the $3.5 trillion industry. | Business Insider | 11/3/2019

… using data from the watch and other Apple devices in studies . Apple’s also been working with insurers like Aetna and UnitedHealthcare . In the case of Aetna, the program is wagering that an app and an … high-profile partnerships with the likes of companies like Walgreens , Novartis , Humana, and West Coast-based health system Providence St. Joseph Health . In addition to providing cloud services, Microsoft also commits to working with its …

Behavioral health providers affiliate to aid in transition to value-based payments | Crain’s New York Business | 10/30/2019

… Novartis, SAP and Urban Outfitters. Henry is in-network for major dental plans such as Aetna, Cigna, Delta Dental and UnitedHealthcare. Its services are billed to those insurers at no extra cost to employers. The company is able to perform preventive and restorative dentistry, such as fillings, and its dentists and hygienists are employees. Clinicians return to offices multiple times a year to establish a relationship with patients. A patient …

Cigna

Second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study | BMJ | 11/1/2019

Cigna HealthManagement, CSL Behring, DP Clinical, Grifols, Hansa Medical, Karos Pharmaceuticals, Neurocrine Biosciences, Novartis, Octapharma, Pharnext, Seattle Genetics, Sun Pharmaceuticals, and Syntimmune. He is on the data and safety monitoring board for Sanofi, Pledpharma, Pfizer, Johnson Roche, Sanofi Genzyme, Teva,TG Therapeutics and UCB. GC has received honoraria from CSL Behring. BCJ has received funding for research projects from Prinses Beatrix Spierfonds, Horizon 2020,GBS-CIDP Foundation International, Grifols, CSL …

Thursday, October 31, 2019 | Kaiser Health News | 10/31/2019

… billion in fiscal year 2018. (Brady, 10/30) Modern Healthcare: Texas Awards Nearly $10 Billion In Medicaid Contracts Health insurers Anthem, Cigna Corp. and Molina Healthcare stand to lose millions in premium revenue after losing ground … as more expensive brand-name drugs. (10/30) And in Reuters: Novartis’ Zolgensma Study Halted By FDA Amid Safety Questions U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety …

Health Net

Second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study | BMJ | 11/1/2019

… MD (Buffalo General Medical Center, Buffalo NY, USA); C.L. Sommer, MD (Universitätsklinikum Würzburg, Würzburg, Germany); J.D. Varrato, DO (Lehigh Valley Health Network, Allentown, USA); J. Verschuuren, MD, PhD (Leiden University Medical Centre, Leiden, The Netherlands … Behring, DP Clinical, Grifols, Hansa Medical, Karos Pharmaceuticals, Neurocrine Biosciences, Novartis, Octapharma, Pharnext, Seattle Genetics, Sun Pharmaceuticals, and Syntimmune. He is on the data and safety monitoring board for Sanofi, Pledpharma, Pfizer, Johnson Roche, Sanofi …

Behavioral health providers affiliate to aid in transition to value-based payments | Crain’s New York Business | 10/30/2019

Reprints Print Advanced Health Network and Recovery Health Solutions—independent practice associations recently awarded state funding as behavioral health care collaboratives—have entered a strategic affiliation. The result is a comprehensive behavioral health network across … Jersey, New York and Pennsylvania. Its clients include Audible, Comcast, Novartis, SAP and Urban Outfitters. Henry is in-network for major dental plans such as Aetna, Cigna, Delta Dental and UnitedHealthcare. Its services are billed …

Molina Healthcare

Thursday, October 31, 2019 | Kaiser Health News | 10/31/2019

… year 2018. (Brady, 10/30) Modern Healthcare: Texas Awards Nearly $10 Billion In Medicaid Contracts Health insurers Anthem, Cigna Corp. and Molina Healthcare stand to lose millions in premium revenue after losing ground in the Texas … as more expensive brand-name drugs. (10/30) And in Reuters: Novartis’ Zolgensma Study Halted By FDA Amid Safety Questions U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety …

Friday, August 23, 2019 | Kaiser Health News | 8/23/2019

… six new states, including Pennsylvania and Georgia, to its current roster of nine. Insurers including Cigna Corp. , Bright Health Inc., Molina Healthcare Inc. and Centene Corp. , the biggest seller of ACA plans, also plan larger … treat. (Rorhich, 8/22) The Wall Street Journal: FDA Focuses On Novartis Delay In Reporting Drug-Test Data Manipulation Federal regulators examining test data manipulation for a gene-therapy drug made by Novartis AG are zeroing …

Bright Health

New Enterprise Associates Promotes Two on Healthcare Investing Team | 10/29/2019

… the firm in 2014. Mathers’ investments have led to numerous positive outcomes including Lumena (acquired by Shire), Ziarco (acquired by Novartis), and Motus Therapeutics (acquired by Allergan), among others. He currently serves on the boards … closely with many NEA portfolio companies including American Pathology Partners, Bright Health, Radiology Partners, and XOC Pharmaceuticals. Prior to joining NEA, he was a member of the private equity group at Ares Management. His earlier …

NEA promotes two | PE Hub | 10/28/2019

… promotion to General Partner.” Mathers’ investments have led to numerous successful outcomes including Lumena (acquired by Shire), Ziarco (acquired by Novartis), and Motus Therapeutics (acquired by Allergan), among others. He currently serves on the boards … closely with many NEA portfolio companies including American Pathology Partners, Bright Health, Radiology Partners, and XOC Pharmaceuticals. Prior to joining NEA, he was a member of the private equity group at Ares Management. His earlier …

Clover Health

Measuring Digital Health Maturity: Review of the Top 10 Pharma Activity 2014-2019 | PR Newswire | 10/26/2019

… more research partnerships than commercial. Digital health related partnership activity across the board has increased almost 5 fold since 2014 Novartis has the most digital health partnerships publicly announced since 2014 Investments and Acquisitions Digital … Abbott Abbvie Akili Almirall Applied VR Bayer Bigfoot BMS Bupa Clover health GlucoMe GSK GuideWell Health Beacon IBM Imperial College Health Partners J&J Livongo Merck MySugr Noona Novartis NovoAir OneDrop Owlstone Partners Healthcare Pfizer …

Measuring Digital Health Maturity: Review of the Top 10 Pharma Activity 2014-2019 | Benzinga | 10/25/2019

… more research partnerships than commercial. Digital health related partnership activity across the board has increased almost 5 fold since 2014 Novartis has the most digital health partnerships publicly announced since 2014 Investments and Acquisitions Digital … Abbott Abbvie Akili Almirall Applied VR Bayer Bigfoot BMS Bupa Clover health GlucoMe GSK GuideWell Health Beacon IBM Imperial College Health Partners J&J Livongo Merck MySugr Noona Novartis NovoAir OneDrop Owlstone Partners Healthcare Pfizer …

Anthem

Concord Health Partners Adds Christi Shaw to Advisory Board | Business Wire | 8/15/2019

… Medicines, overseeing late-stage clinical development and commercialization for the company’s Immunology, Pain, Migraine and Alzheimer’s Disease therapeutic areas. Prior to joining Lilly, Ms. Shaw served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology. She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin. “Having seen such remarkable advances in healthcare over the …

CB Stock Price - Chubb Ltd. Stock Quote (U.S.- NYSE) | MarketWatch | 5/23/2019

Novartis AG, Cigna Corp, Sells Fox Corp, Anthem Inc, Johnson & Johnson May. 9, 2019 at 1:38 p.m. ET on GuruFocus.com Everest Re Group, Ltd. Appoints Meryl Hartzband to the Board of Directors May. 23, 2019 at 2:29 p.m. ET on BusinessWire - BZX Business Travel Accident Insurance Market Analysis and Forecast From 2019 - 2024: Assicurazioni Generali, MetLife, Nationwide Mutual Insurance, Zurich, AWP Australia, AXA, American International, Chubb, Tokio Marine Holdings May …

Harvard Pilgrim Health Care

Boston drug-pricing watchdog group has pharma companies’ attention - The Boston Globe | 6/19/2019

… some of the world’s biggest drug makers charge for their products. Just last month, the head of Swiss drug giant Novartis said he could justify a price tag of up to $5 million for a … said Michael Sherman, a physician and chief medical officer for Harvard Pilgrim Health Care, the second-largest private insurer in Massachusetts. “As we come to the realization that we don’t have an unlimited global budget …

The gene therapy era has arrived. So have the challenges. | 6/7/2019

Harvard Pilgrim Health Care, in an interview with BioPharma Dive on the sidelines of the 2019 BIO conference in Philadelphia. A similar logic applies to Spark Therapeutics’ Luxturna, a gene therapy approved in the U.S. in December 2017 to treat a rare form of blindness. Novartis’ Zolgensma and Spark’s Luxturna are just the first in what’s expected to be a wave of experimental gene therapies to make it to market …

Donald Trump

Chutes & Ladders—Teva names replacement for outgoing CFO McClellan | FierceBiotech | 11/7/2019

… over for Ned Sharpless , who had been running the U.S. regulator on an interim basis since Scott Gottlieb , another President Donald Trump pick, left in the spring. Sharpless had been a front-runner, but Hahn … leadership roles with MorphoSys US, Ariad Pharmaceuticals, Bristol-Myers Squibb, Novartis Oncology and SmithKline Beecham Oncology. Release San Francisco-based Imago BioSciences appointed James D. Watson as CBO. Watson most recently served as CBO at …

The European Union agreed on Monday to delay Brexit until | 11/6/2019

… Jack Hughes will make the Devils successful and relevant again. THIS IS AN AUDIO ONLY PRODUCTION. A woman who accuses Donald Trump of raping her more than 23 years ago in a New York department … at their home in Yandaran in Queensland in September 2017. Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill …

Elizabeth Warren

How A Computer Model Prices the Value Of Good Health and Moderates Drug Costs | 11/7/2019

… Elizabeth Warren, pharmaceutical companies have started paying attention. Novartis AG set the price of its lifesaving gene therapy Zolgensma at the limit suggested by ICER, as the Boston group is known. Dave Lennon, president of the Novartis unit that makes it, says ICER had brought transparency to drug-price analysis. “Whatever pricing we believe will be appropriate for a product will be compared to what ICER did,” he says. The …

Ridiculous D.C. Invite of the Week, Joe Biden Fundraiser … | 11/7/2019

… Matt Rourke/AP Photo Former Vice President Joe Biden at the University of Pennsylvania, April 2019 Joe Biden continued his “Elizabeth Warren is an elitist” tour last night with three separate high-dollar fundraisers, including … co-founded his own firm with his brother, personally representing Novartis, Eli Lilly, Sanofi, and the American Hospital Association. Ricchetti’s brother still lobbies in the healthcare space while Ricchetti serves as chairman of a Democratic …

Michel Vounatsos

Biogen and Samsung expand biosimilar deal to cover Lucentis, Eylea and China | FiercePharma | 11/7/2019

… China, too. Biogen is getting exclusive rights to Samsung Biopeis’ biosimilar versions of two blockbuster eye drugs, namely Roche and Novartis’ Lucentis and Regeneron and Bayer’s Eylea, covering the U.S., Europe, Japan and other key … broad access to care for patients in need,” Biogen CEO Michel Vounatsos said in a statement. Currently, Biogen’s anti-TNF portfolio is only available in the EU, and sales there seem to have hit a …

Biogen’s Spinraza is still churning—even after Novartis’ rival Zolgensma launch | FiercePharma | 10/23/2019

Biogen’s Spinraza has faced its first full quarter of competition from Novartis’ gene therapy Zolgensma and early figures show the meds might be able to grow sales alongside one another. The Boston biotech on Tuesday … med wouldn’t benefit patients. On Tuesday’s conference call, Biogen CEO Michel Vounatsos said that earlier analysis was “incorrect” because it “didn’t effectively evaluate all of the variables” in two phase 3 trials assessing the med …

John Miller

Novartis says delayed telling FDA of Zolgensma concern due to ‘mistake’ | Yahoo News | 11/1/2019

Novartis scientists learnt months ago about safety concerns surrounding its gene therapy Zolgensma but delayed telling the U.S. Food and Drug Administration (FDA) due to what the Swiss drugmaker said was a “mistake”.” data-reactid … additional actions necessary to resume dosing,” Novartis said. (Reporting by John Miller; Emelia Sithole-Matarise …

Novartis says delayed telling FDA of Zolgensma concern due to ‘mistake’ | 11/1/2019

ZURICH (Reuters) – Novartis scientists learnt months ago about safety concerns surrounding its gene therapy Zolgensma but delayed telling the U.S. Food and Drug Administration (FDA) due to what the Swiss drugmaker said was a “mistake … additional actions necessary to resume dosing,” Novartis said. (Reporting by John Miller; Emelia Sithole-Matarise) Share …

Nick Taylor

EuroBiotech Report—Roche-Dicerna, GSK in TB, Sanifit data, filgotinib and Novartis | FierceBiotech | 10/31/2019

Novartis missed the mark in atopic dermatitis. And more. — Nick Taylor 1. Roche pays $200M for rights to Dicerna’s hepatitis B RNAi drug Roche is paying Dicerna Pharmaceuticals $200 million (€179 million) upfront for a global license to phase 1 hepatitis B prospect DCR-HBVS. The deal, which will see Roche and Dicerna collaborate on other hepatitis B virus assets, is worth up to $1.5 billion in milestones. GlaxoSmithKline has …

EuroBiotech Report—UCB beats J&J, Novartis fail, AstraZeneca, NASH deal and Evotec | FierceBiotech | 10/24/2019

Novartis revealed its asthma prospect has failed a pivotal test. Novartis was also in the news for betting $80 million on Pliant Therapeutics’ preclinical NASH prospect. Evotec expanded its early stage accelerator model to Israel. And more. — Nick Taylor 1. UCB’s bispecific beats J&J’s Stelara in psoriasis phase 3 UCB’s bimekizumab has beaten Johnson & Johnson’s Stelara in a phase 3 psoriasis trial. The bispecific inhibitor of IL-17A and …

Alex Azar

Thursday, October 31, 2019 | Kaiser Health News | 10/31/2019

… than 50 health and advocacy groups are sending a clear message in letters to US Health and Human Services Secretary Alex Azar and first lady Melania Trump: Stick with the plan that was announced last … as more expensive brand-name drugs. (10/30) And in Reuters: Novartis’ Zolgensma Study Halted By FDA Amid Safety Questions U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety …

Former Express Scripts lobbyist heads to BCW - POLITICO | 10/23/2019

… to a disclosure filing. United Technologies is planning to merge with Raytheon in a deal that requires regulators’ signoff. And Novartis has added the Watts Group to its own deep bench of outside lobbying firms … for drug pricing reform to Health and Human Services Secretary Alex Azar . — Former Virginia Gov. Terry McAuliffe is joining Hunton Andrews Kurth as global strategy adviser at the Centre for Information Policy Leadership, the firm’s …

Bob Bradway

Amgen Exits Neuroscience Research: The Good, Bad, And Ugly Of Biopharma - Amgen Inc. (NASDAQ:AMGN) | Seeking Alpha | 10/31/2019

Novartis ( NVS ) was halted a few months back. In response to a caller’s question about the neuroscience decision, David said that the company was looking at alternative models to maintain a hand in the neuroscience segment. It could potentially be with venture capital or maybe academic institutions. The company’s CEO, Bob Bradway added that Amgen would capitalize on the insights from its work with deCODE in human genome sequencing. Amgen’s …

As Amgen zeroes in on cancer, neuroscience pipeline under the ax | FierceBiotech | 10/30/2019

… genetics will ultimately drive progress in this area and we’ll continue to work with deCODE to generate insights.” Amgen CEO Bob Bradway added: “I would just add on the last point that half the genes … also comes a few months after Amgen and drug partner Novartis ditched pivotal tests of CNP520 in Alzheimer’s disease after an interim review found patients on the BACE inhibitor worsened on some measures of cognitive …

Brian Kaspar

FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy | 10/30/2019

The FDA has imposed a partial hold on clinical trials for intrathecal administration of Novartis’ AVXS-101, a gene therapy won the agency’s first approval for treating some forms of spinal muscular atrophy (SMA) in … alerting the FDA. AveXis replaced its two top scientific executives—Brian Kaspar, PhD, previously CSO and Allan Kaspar, PhD, previously senior vice president research and development—with a single executive, Page Bouchard, DVM, who was …

Novartis’ Zolgensma faces EU, Japan delays after regulators raise ‘manufacturing questions’ | FiercePharma | 10/23/2019

Novartis’ Zolgensma launch has been anything but boring: First a record-setting price tag, then a data-manipulation scandal and, with Tuesday earnings, a Street-beating first quarter on the market. And now, on top … at AveXis after former chief scientific officer and company founder Brian Kaspar and his brother Allan Kaspar were fired for allegedly spearheading the scandal. Brian Kasper has denied the allegations through an attorney. Additionally, Novartis

Allan Kaspar

FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy | 10/30/2019

The FDA has imposed a partial hold on clinical trials for intrathecal administration of Novartis’ AVXS-101, a gene therapy won the agency’s first approval for treating some forms of spinal muscular atrophy (SMA) in … two top scientific executives—Brian Kaspar, PhD, previously CSO and Allan Kaspar, PhD, previously senior vice president research and development—with a single executive, Page Bouchard, DVM, who was appointed senior vice president of research …

Novartis’ Zolgensma faces EU, Japan delays after regulators raise ‘manufacturing questions’ | FiercePharma | 10/23/2019

Novartis’ Zolgensma launch has been anything but boring: First a record-setting price tag, then a data-manipulation scandal and, with Tuesday earnings, a Street-beating first quarter on the market. And now, on top … scientific officer and company founder Brian Kaspar and his brother Allan Kaspar were fired for allegedly spearheading the scandal. Brian Kasper has denied the allegations through an attorney. Additionally, Novartis will have the AveXis head …

David Reese

As Amgen zeroes in on cancer, neuroscience pipeline under the ax | FierceBiotech | 10/30/2019

… the biopharma company is looking to slim down its efforts in that area. Talking on their financial call late Tuesday, David Reese, executive vice president of R&D at Amgen, explained: “I’d like to say … also comes a few months after Amgen and drug partner Novartis ditched pivotal tests of CNP520 in Alzheimer’s disease after an interim review found patients on the BACE inhibitor worsened on some measures of cognitive …